Palbociclib plus letrozole clinical outcomes PALOMA-2

In PALOMA-2, palbociclib plus letrozole significantly improved progression-free survival by 13 months compared to letrozole alone (27.6 vs 14.5 months) with manageable hematologic toxicity and maintained quality of life, but did not demonstrate a significant overall survival benefit after 90 months of follow-up.

Abstract

The PALOMA-2 trial demonstrated that palbociclib plus letrozole significantly improved progression-free survival compared to placebo plus letrozole in postmenopausal women with ER+/HER2- advanced breast cancer. Median PFS was 27.6 months versus 14.5 months (HR 0.56, P<0.0001), with consistent benefit observed across all patient subgroups including Asian patients (25.7 vs 13.9 months, HR 0.49, P=0.007) and those with low disease burden. Notably, PFS improvement occurred regardless of objective response status, with non-responders experiencing median PFS of 10.9 versus 5.6 months (HR 0.72, P=0.016). The treatment delayed time to subsequent chemotherapy by approximately 10 months (40.4 vs 29.9 months). However, after 90.1 months of follow-up, median overall survival was 53.9 versus 51.2 months (HR 0.96, P=0.34), showing no significant improvement.

The primary toxicity was hematologic, with grade 3-4 neutropenia occurring in 66.4% of patients (vs 1.4% with placebo), increasing to 89.2% in Asian populations. Despite this, febrile neutropenia remained rare (1.8-2.0%), and treatment discontinuation rates were low (9.7-12.2% vs 5.9%). Quality of life was maintained with no significant differences in FACT-Breast Total or EQ-5D scores between treatment arms, and pain scores significantly improved with palbociclib plus letrozole (P=0.0183). Neutropenia did not negatively impact quality of life measures.

Methods

We analyzed 10 sources from an initial pool of 200, using 6 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question.

Characteristics of Included Studies

The included publications comprised analyses from the PALOMA-2 trial, a phase 3 randomized controlled trial that enrolled 666 postmenopausal women with ER+/HER2- advanced breast cancer. Patients were randomized 2:1 to palbociclib plus letrozole (n=444) or placebo plus letrozole (n=222). Key eligibility criteria included no prior systemic therapy for advanced disease and performance status 0-2. Disease characteristics at baseline included measurable disease in 76-77% of patients, with approximately 48% having visceral disease and 52% non-visceral disease.

Efficacy Outcomes

Progression-Free Survival

Across all analyses, palbociclib plus letrozole demonstrated consistent improvement in PFS compared to placebo plus letrozole. In the primary analysis, median PFS was 24.8 months versus 14.5 months (HR 0.58, 95% CI 0.46-0.72, P<0.001). With extended follow-up of approximately 38 months, median PFS was 27.6 months versus 14.5 months (HR 0.56, P<0.0001), confirming the sustained benefit.

Analysis

Overall Survival

After a median follow-up of 90.1 months, median OS was 53.9 months (95% CI 49.8-60.8) with palbociclib plus letrozole versus 51.2 months (95% CI 43.7-58.9) with placebo plus letrozole (HR 0.96, 95% CI 0.78-1.18, one-sided P=0.34). The study did not demonstrate a statistically significant improvement in OS.

Safety Outcomes

Hematologic Toxicities

Neutropenia was the most common adverse event, occurring in 66.4% of patients (grade 3-4) in the palbociclib-letrozole arm versus 1.4% in the placebo-letrozole arm. In the extended follow-up analysis, neutropenia occurred in 81.8-82.2% of patients in the palbociclib arm.

Adverse event

Patient-Reported Outcomes and Quality of Life

Patient-reported outcomes were assessed using the Functional Assessment of Cancer Therapy-Breast (FACT-Breast) and EuroQol 5 dimensions (EQ-5D) questionnaires. Baseline QOL scores were comparable between treatment arms.

QOL Measure

The addition of palbociclib to letrozole maintained health-related QOL and improved pain scores compared to letrozole alone. Time to deterioration of FACT-Breast Total score was significantly delayed in patients without progression versus those with progression, and in patients with partial or complete response versus non-responders. No significant difference was observed in FACT-Breast and EQ-5D index scores between patients with and without neutropenia, indicating that neutropenia did not negatively impact QOL despite being a common adverse event.

Subgroup Analyses

All subgroups analyzed demonstrated benefit from the addition of palbociclib to letrozole. Patients with low disease burden, including those with non-measurable disease, bone-only disease, or single disease site, derived significant PFS benefit.

Subgroup Analysis